Protocol version 5.0 Changes: The protocol was amended due to questions released by the German Federal Institute for Drugs and Medical Devices (BfArM) on 09 December 2011 and the German Ethics Committee (EC) on 04 January 2012. As the new protocol was submitted in other countries, inclusion criterion #6 was updated, inclusion criterion #12 and exclusion criterion #2 were clarified and exclusion criterion #21 was added at the same time. Inclusion criterion 6 was changed: • From: Have documented SCI or MS with urodynamic measurement abnormalities within 6 months (both complete and incomplete SCIs and relevant MS with confirmed NDO as defined by ICS guidelines will be included in this study) • To: Have documented SCI or MS (both complete and incomplete SCIs and relevant MS with confirmed NDO as defined by ICS guidelines will be included in this study). Inclusion criterion 12 was changed: • From: Female subjects of childbearing potential must have a negative pregnancy test result and be willing to use reliable contraceptive measures for the duration of the study • To: Female subjects of childbearing potential must have had a negative pregnancy test result and have been willing to use reliable contraceptive measures for the duration the study (i.e. oral contraceptives and spermicide, when used in combination with condoms, etc. as a ‘double barrier method’) Exclusion criterion 2 was changed • From: Previous or current requirement for/diagnosis of bladder or and urethral disease or surgery, or disease/prostate cancer (PSA of >10 ng/mL). Subjects with serum PSA concentrations >4 ng/mL and <10 ng/mL must have prostate cancer excluded • To: Previous or current diagnosis of bladder and urethral disease or surgery, or prostate cancer (PSA of >10 ng/mL). Subjects with serum PSA concentrations >4 ng/mL and <10 ng/mL must have prostate cancer excluded. In light of this amendment, the CRF, local consent form, database and RAP required updating.

Protocol version 6.0 The protocol was amended to increase the number of participating centres (from approximately 8 to 10 to 22 centres) and to reduce the sample size following difficulties in recruitment. The sections on Sample Size Determination were changed • From: This is a preliminary, pilot study with a limited number of subjects where the sample size of 56 subjects was based on the clinical judgement/practical constraints and not on statistical considerations. A total of 56 subjects will be randomised in this study, out of which: - 20 will receive Dysport 750 U, 0.5 mL in 15 sites - 8 will receive placebo, 0.5 mL in 15 sites - 20 will receive Dysport 750 U, 0.5 mL in 30 sites - 8 will receive placebo, 0.5 mL in 30 sites. • To: This is a preliminary, pilot study with a limited number of subjects where the sample size of at least 42 subjects was based on the clinical judgement/practical constraints and not on statistical considerations. A total of at least 42 subjects will be randomised in this study, out of which: - At least 15 will receive Dysport 750 U, 0.5 mL in 15 sites - At least 6 will receive placebo, 0.5 mL in 15 sites - At least 15 will receive Dysport 750 U, 0.5 mL in 30 sites - At least 6 will receive placebo, 0.5 mL in 30 sites. The protocol was also amended to allow the replacement of subjects who were randomised but who were not assessed on the primary efficacy variable at Baseline. In light of this amendment, the local consent form and RAP required updating.